The new report from US Surgeon General Vivek H. Murthy, MD, MBA, highlights persistent disparities in tobacco use and ...

Reducing systolic blood pressure to less than 120 mmHg lowered the risk of major cardiovascular events for most people with ...

Community-based researchers can teach clinicians a lot about how to best approach underserved populations disproportionately impacted by cardiovascular health complications.

Panelists discuss the methodologies of the OASIS 1, 2, and 3 trials that investigated elinzanetant, highlighting key findings ...

Elinzanetant showed significant efficacy in reducing VMS frequency and severity, with rapid symptom improvement compared to ...

Mavacamten is approved for treating obstructive hypertrophic cardiomyopathy, with real-world data supporting its safety and efficacy. The REMS program is crucial for monitoring mavacamten's safety ...

Forecasts indicate a drastic increase in US obesity rates in the next 25 years, emphasizing the need for comprehensive public ...

An update from the PURPOSE 2 trial focused on adherence and pharmacokinetics data for lenacapavir, used to prevent HIV.

Of the 518 hospitals that had at least 10 eligible discharges, only 11 of them prescribed SGLT2 inhibitors to more than half ...

New discoveries in atherosclerosis pathways have shed light on the active mechanisms in other diseases such as chronic kidney disease (CKD) and HIV, paving the way for furture therapeutics.

The FINEARTS-HF trial offered novel clinical insights as one of the few cardiovascular trials to feature such a great proportion of female participants.

The SARAH trial was limited to high-risk patients, which the lead investigator said prevented unnecessary exposure to adverse ...